Table of Content

1. Key Insights

2. Executive Summary of Multiple Myeloma (MM)

3. KOL Views

4. SWOT Analysis of Multiple Myeloma (MM)

5. Multiple Myeloma: Market Overview at a Glance

6. Disease Background and Overview: Multiple Myeloma (MM)
6.1. Introduction
6.2. Multiple Myeloma features
6.2.1. Low blood counts
6.2.2. Bone and calcium problems
6.2.3. Infections
6.2.4. Kidney problems
6.3. Causes of Multiple Myeloma
6.4. Risk factors of Multiple Myeloma
6.5. Signs and Symptoms
6.5.1. Bone Problems
6.5.2. Low blood counts
6.5.3. High blood levels of calcium
6.5.4. Nervous system symptoms
6.5.5. Kidney Problems
6.5.6. Infections
6.6. Pathogenesis of Multiple Myeloma
6.6.1. Molecular mechanisms underlying the progression of multiple myeloma
6.6.2. Molecular pathogenesis of multiple myeloma and its premalignant precursor
6.7. Pathophysiology of Multiple Myeloma
6.8. Patient-related risk factors
6.9. Biomarkers for Multiple Myeloma
6.9.1. Serum M-protein and light chains as biomarkers
6.9.2. Potential proteomic biomarkers
6.9.3. Cytogenetic biomarkers in multiple myeloma

7. Diagnosis of Multiple Myeloma
7.1. Lab tests
7.2. Biopsies
7.3. Imaging tests
7.4. Stages of Multiple Myeloma

8. Epidemiology and Patient Population
8.1. Epidemiology Key Findings
8.2. Assumptions and Rationale: 8MM
8.3. Epidemiology Scenario: 8MM
8.3.1. Total Incident Cases of Multiple Myeloma in the 8MM
8.3.2. Total Symptomatic Cases of Multiple Myeloma in the 8MM
8.3.3. Gender-specific cases of Multiple Myeloma in the 8MM
8.3.4. Diagnosed cases of Multiple Myeloma by Age Distribution in the 8MM
8.3.5. Cases of Multiple Myeloma by Treatment Line in the 8MM

9. The United States Epidemiology
9.1. Total Incident Cases of Multiple Myeloma in the United States
9.2. Total Symptomatic Cases of Multiple Myeloma in the United States
9.3. Gender-specific cases of Multiple Myeloma in the United States
9.4. Diagnosed cases of Multiple Myeloma by Age Distribution in the United States
9.5. Cases of Multiple Myeloma by Treatment Line in the United States

10. EU-5 Epidemiology
10.1. Germany
10.1.1. Total Incident Cases of Multiple Myeloma in Germany
10.1.2. Total Symptomatic Cases of Multiple Myeloma in Germany
10.1.3. Gender-specific cases of Multiple Myeloma in Germany
10.1.4. Diagnosed cases of Multiple Myeloma by Age Distribution in Germany
10.1.5. Cases of Multiple Myeloma by Treatment Line in Germany
10.2. France
10.2.1. Total Incident Cases of Multiple Myeloma in France
10.2.2. Total Symptomatic Cases of Multiple Myeloma in France
10.2.3. Gender-specific cases of Multiple Myeloma in France
10.2.4. Diagnosed cases of Multiple Myeloma by Age Distribution in France
10.2.5. Cases of Multiple Myeloma by Treatment Line in France
10.3. Italy
10.3.1. Total Incident Cases of Multiple Myeloma in Italy
10.3.2. Total Symptomatic Cases of Multiple Myeloma in Italy
10.3.3. Gender-specific cases of Multiple Myeloma in Italy
10.3.4. Diagnosed cases of Multiple Myeloma by Age Distribution in Italy
10.3.5. Cases of Multiple Myeloma by Treatment Line in Italy
10.4. Spain
10.4.1. Total Incident Cases of Multiple Myeloma in Spain
10.4.2. Total Symptomatic Cases of Multiple Myeloma in Spain
10.4.3. Gender-specific cases of Multiple Myeloma in Spain
10.4.4. Diagnosed cases of Multiple Myeloma by Age Distribution in Spain
10.4.5. Cases of Multiple Myeloma by Treatment Line in Spain
10.5. The United Kingdom
10.5.1. Total Incident Cases of Multiple Myeloma in the United Kingdom
10.5.2. Total Symptomatic Cases of Multiple Myeloma in the United Kingdom
10.5.3. Gender-specific cases of Multiple Myeloma in the United Kingdom
10.5.4. Diagnosed cases of Multiple Myeloma by Age Distribution in the United Kingdom
10.5.5. Cases of Multiple Myeloma by Treatment Line in the United Kingdom

11. Japan Epidemiology
11.1. Japan
11.1.1. Total Incident Cases of Multiple Myeloma in Japan
11.1.2. Total Symptomatic Cases of Multiple Myeloma in Japan
11.1.3. Gender-specific cases of Multiple Myeloma in Japan
11.1.4. Diagnosed cases of Multiple Myeloma by Age Distribution in Japan
11.1.5. Cases of Multiple Myeloma by Treatment Line in Japan

12. China Epidemiology
12.1. China
12.1.1. Total Incident Cases of Multiple Myeloma in China
12.1.2. Total Symptomatic Cases of Multiple Myeloma in China
12.1.3. Gender-specific cases of Multiple Myeloma in China
12.1.4. Diagnosed cases of Multiple Myeloma by Age Distribution in China
12.1.5. Cases of Multiple Myeloma by Treatment Line in China

13. Appendix
13.1. Bibliography
13.2. Report Methodology

14. DelveInsight Capabilities

15. Disclaimer

16. About DelveInsight



List of Figures


Figure 1 Multiple Myeloma (MM) SWOT Analysis
Figure 2 Interactions of MM tumor cells with the BM microenvironment. Five kinds of cells in the BM microenvironment are depicted, as well as a few of the complex interactions among these cells and MM cells.
Figure 3 Interaction of multiple myeloma cells in their bone marrow milieu
Figure 4 Technological advances in detecting biomarkers in multiple myeloma.
Figure 5 The National Comprehensive Cancer Network (NCCN) recommendations for initial diagnostic workup of patients with suspected MM
Figure 6 Global Heat Map of Multiple Myeloma
Figure 7 Total Incident Cases of Multiple Myeloma in the 8MM (2017–2030)
Figure 8 Symptomatic Cases of Multiple Myeloma in the 8MM (2017–2030)
Figure 9 Gender-specific cases of Multiple Myeloma in the 8MM (2017–2030)
Figure 10 Diagnosed cases of Multiple Myeloma by Age Distribution in the 8MM (2017–2030)
Figure 11 Cases of Multiple Myeloma by Treatment Line in the 8MM (2017–2030)
Figure 12 Total Incident Cases of Multiple Myeloma in the United States (2017–2030)
Figure 13 Symptomatic Cases of Multiple Myeloma in the United States (2017–2030)
Figure 14 Gender-specific cases of Multiple Myeloma in the United States (2017–2030)
Figure 15 Diagnosed cases of Multiple Myeloma by Age Distribution in the United States (2017–2030)
Figure 16 Cases of Multiple Myeloma by Treatment Line in the United States (2017–2030)
Figure 17 Total Incident Cases of Multiple Myeloma in Germany (2017–2030)
Figure 18 Symptomatic Cases of Multiple Myeloma in Germany (2017–2030)
Figure 19 Gender-specific cases of Multiple Myeloma in Germany (2017–2030)
Figure 20 Diagnosed cases of Multiple Myeloma by Age Distribution in Germany (2017–2030)
Figure 21 Cases of Multiple Myeloma by Treatment Line in Germany (2017–2030)
Figure 22 Total Incident Cases of Multiple Myeloma in France (2017–2030)
Figure 23 Symptomatic Cases of Multiple Myeloma in France (2017–2030)
Figure 24 Gender-specific cases of Multiple Myeloma in France (2017–2030)
Figure 25 Diagnosed cases of Multiple Myeloma by Age Distribution in France (2017–2030)
Figure 26 Cases of Multiple Myeloma by Treatment Line in France (2017–2030)
Figure 27 Total Incident Cases of Multiple Myeloma in Italy (2017–2030)
Figure 28 Symptomatic Cases of Multiple Myeloma in Italy (2017–2030)
Figure 29 Gender-specific cases of Multiple Myeloma in Italy (2017–2030)
Figure 30 Diagnosed cases of Multiple Myeloma by Age Distribution in Italy (2017–2030)
Figure 31 Cases of Multiple Myeloma by Treatment Line in Italy (2017–2030)
Figure 32 Total Incident Cases of Multiple Myeloma in Spain (2017–2030)
Figure 33 Symptomatic Cases of Multiple Myeloma in Spain (2017–2030)
Figure 34 Gender-specific cases of Multiple Myeloma in Spain (2017–2030)
Figure 35 Diagnosed cases of Multiple Myeloma by Age Distribution in Spain (2017–2030)
Figure 36 Cases of Multiple Myeloma by Treatment Line in Spain (2017–2030)
Figure 37 Total Incident Cases of Multiple Myeloma in the United Kingdom (2017–2030)
Figure 38 Symptomatic Cases of Multiple Myeloma in the United Kingdom (2017–2030)
Figure 39 Gender-specific cases of Multiple Myeloma in the United Kingdom (2017–2030)
Figure 40 Diagnosed cases of Multiple Myeloma by Age Distribution in the United Kingdom (2017–2030)
Figure 41 Cases of Multiple Myeloma by Treatment Line in the United Kingdom (2017–2030)
Figure 42 Total Incident Cases of Multiple Myeloma in Japan (2017–2030)
Figure 43 Symptomatic Cases of Multiple Myeloma in Japan (2017–2030)
Figure 44 Gender-specific cases of Multiple Myeloma in Japan (2017–2030)
Figure 45 Diagnosed cases of Multiple Myeloma by Age Distribution in Japan (2017–2030)
Figure 46 Cases of Multiple Myeloma by Treatment Line in Japan (2017–2030)
Figure 47 Total Incident Cases of Multiple Myeloma in China (2017–2030)
Figure 48 Symptomatic Cases of Multiple Myeloma in China (2017–2030)
Figure 49 Gender-specific cases of Multiple Myeloma in China (2017–2030)
Figure 50 Diagnosed cases of Multiple Myeloma by Age Distribution in China (2017–2030)
Figure 51 Cases of Multiple Myeloma by Treatment Line in China (2017–2030)


List of Tables


Table 1 Summary of MM Market, Epidemiology, and Key Events (2017–2030)
Table 2 Cytogenetic Abnormalities on Clinical Course and Prognosis in Multiple Myeloma
Table 3 The Revised International Staging System
Table 4 International Myeloma Working Group (IMWG) Diagnostic Criteria for Multiple Myeloma and Related Plasma Cell Disorders
Table 5 Recommendations for the use of __F-FDG PET/CT in patients with multiple myeloma and other plasma cell disorders
Table 6 Total Incident Cases of Multiple Myeloma in the 8MM (2017–2030)
Table 7 Total Symptomatic Cases of Multiple Myeloma in the 8MM (2017–2030)
Table 8 Gender-specific cases of Multiple Myeloma in the 8MM (2017–2030)
Table 9 Diagnosed cases of Multiple Myeloma by Age Distribution in the 8MM (2017–2030)
Table 10 Cases of Multiple Myeloma by Treatment Line in the 8MM (2017–2030)
Table 11 Total Incident Cases of Multiple Myeloma in the United States (2017–2030)
Table 12 Total Symptomatic Cases of Multiple Myeloma in the United States (2017–2030)
Table 13 Gender-specific cases of Multiple Myeloma in the United States (2017–2030)
Table 14 Diagnosed cases of Multiple Myeloma by Age Distribution in the United States (2017–2030)
Table 15 Cases of Multiple Myeloma by Treatment Line in the United States (2017–2030)
Table 16 Total Incident Cases of Multiple Myeloma in Germany (2017–2030)
Table 17 Total Symptomatic Cases of Multiple Myeloma in Germany (2017–2030)
Table 18 Gender-specific cases of Multiple Myeloma in Germany (2017–2030)
Table 19 Diagnosed cases of Multiple Myeloma by Age Distribution in Germany (2017–2030)
Table 20 Cases of Multiple Myeloma by Treatment Line in Germany (2017–2030)
Table 21 Total Incident Cases of Multiple Myeloma in France (2017–2030)
Table 22 Total Symptomatic Cases of Multiple Myeloma in France (2017–2030)
Table 23 Gender-specific cases of Multiple Myeloma in France (2017–2030)
Table 24 Diagnosed cases of Multiple Myeloma by Age Distribution in France (2017–2030)
Table 25 Cases of Multiple Myeloma by Treatment Line in France (2017–2030)
Table 26 Total Incident Cases of Multiple Myeloma in Italy (2017–2030)
Table 27 Total Symptomatic Cases of Multiple Myeloma in Italy (2017–2030)
Table 28 Gender-specific cases of Multiple Myeloma in Italy (2017–2030)
Table 29 Diagnosed cases of Multiple Myeloma by Age Distribution in Italy (2017–2030)
Table 30 Cases of Multiple Myeloma by Treatment Line in Italy (2017–2030)
Table 31 Total Incident Cases of Multiple Myeloma in Spain (2017–2030)
Table 32 Total Symptomatic Cases of Multiple Myeloma in Spain (2017–2030)
Table 33 Gender-specific cases of Multiple Myeloma in Spain (2017–2030)
Table 34 Diagnosed cases of Multiple Myeloma by Age Distribution in Spain (2017–2030)
Table 35 Cases of Multiple Myeloma by Treatment Line in Spain (2017–2030)
Table 36 Total Incident Cases of Multiple Myeloma in the United Kingdom (2017–2030)
Table 37 Total Symptomatic Cases of Multiple Myeloma in the United Kingdom (2017–2030)
Table 38 Gender-specific cases of Multiple Myeloma in the United Kingdom (2017–2030)
Table 39 Diagnosed cases of Multiple Myeloma by Age Distribution in the United Kingdom (2017–2030)
Table 40 Cases of Multiple Myeloma by Treatment Line in the United Kingdom (2017–2030)
Table 41 Total Incident Cases of Multiple Myeloma in Japan (2017–2030)
Table 42 Total Symptomatic Cases of Multiple Myeloma in Japan (2017–2030)
Table 43 Gender-specific cases of Multiple Myeloma in Japan (2017–2030)
Table 44 Diagnosed cases of Multiple Myeloma by Age Distribution in Japan (2017–2030)
Table 45 Cases of Multiple Myeloma by Treatment Line in Japan (2017–2030)
Table 46 Total Incident Cases of Multiple Myeloma in China (2017–2030)
Table 47 Total Symptomatic Cases of Multiple Myeloma in China (2017–2030)
Table 48 Gender-specific cases of Multiple Myeloma in China (2017–2030)
Table 49 Diagnosed cases of Multiple Myeloma by Age Distribution in China (2017–2030)
Table 50 Cases of Multiple Myeloma by Treatment Line in China (2017–2030)